|
1.
|
|
11 p, 21.0 MB |
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
/
Tavira, Beatriz (Cancer Center Clínica Universidad de Navarra) ;
Iscar, Teresa (Cancer Center Clínica Universidad de Navarra) ;
Manso, Luis (Hospital 12 de Octubre (Madrid)) ;
Santaballa, Ana (Hospital Universitari i Politècnic La Fe (València)) ;
Gil-Martin, Marta (Institut Català d'Oncologia - Hospital Duran i Reynals) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Iglesias, Maria (Hospital Son Llátzer) ;
de Juan Ferre, Ana (Hospital Marqués de Valdecilla) ;
Barretina-Ginesta, Maria-Pilar (Institut Català d'Oncologia) ;
Manzano, Aranzazu (Hospital Clínico San Carlos (Madrid)) ;
Gaba, Lydia (Hospital Clínic i Provincial de Barcelona) ;
Rubio, Maria Jesus (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
de Andrea, Carlos E. (Centro de Investigación Biomédica en Red de Cáncer) ;
González-Martín, Antonio (Cancer Center Clínica Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients. [...]
2023 -  10.1158/1078-0432.CCR-23-0771
Clinical Cancer Research, Vol. 30 (august 2023) , p. 176-186
|
|
|
2.
|
|
11 p, 618.2 KB |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities : Laboratory tools for an early and differential diagnosis
/
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Fernández, Sara (Hospital Clínic i Provincial de Barcelona) ;
Ventosa, Helena (Hospital Clínic i Provincial de Barcelona) ;
Palomo, Marta (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Fernández De Larrea, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Penack, Olaf (Charité Universitätsmedizin Berlin, Germany) ;
Nicolás, J.M. (Hospital Clínic i Provincial de Barcelona) ;
Téllez, Adrian (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Gines (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Castro Rebollo, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. [...]
2023 - 10.1136/jitc-2022-006365
Journal for immunotherapy of cancer, Vol. 11 Núm. 4 (april 2023)
|
|
|
3.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 - 10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
4.
|
|
15 p, 4.7 MB |
Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer
/
Ortiz-Barahona, Vanessa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Prieto, Carlos A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Janin, Maxime (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Setien, Fernando (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Rebollo, Irene (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bech-Serra, Joan J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De La Torre, Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guil, Sonia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Zhang, Pei Hong (Fudan University, Shanghai, China) ;
Yang, Li (Fudan University, Shanghai, China) ;
Guarnacci, Marco (Australian National University, Canberra, Australia) ;
Schumann, Ulrike (Australian National University, Canberra, Australia) ;
Preiss, Thomas (Australian National University, Canberra, Australia) ;
Balaseviciute, Ugne (Hospital Clínic i Provincial de Barcelona) ;
Montal, Robert (Universitat de Lleida) ;
Llovet, Josep M. (Hospital Clínic i Provincial de Barcelona) ;
Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Background: RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. [...]
2023 - 10.1186/s12943-023-01785-z
Molecular cancer, Vol. 22 Núm. 1 (may 2023)
|
|
|
5.
|
|
14 p, 7.4 MB |
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors
/
Llinàs-Arias, Pere (Institut d'Investigació Sanitària Illes Balears) ;
Ensenyat-Mendez, Miquel (Cancer Epigenetics Laboratory. Health Research Institute of the Balearic Islands (IdISBa)) ;
Íñiguez-Muñoz, Sandra (Cancer Epigenetics Laboratory. Health Research Institute of the Balearic Islands (IdISBa)) ;
Orozco, Javier I.J. (Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA) ;
Valdez, Betsy (Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.) ;
Salomon, Matthew P. (University of Southern California, Los Angeles, USA) ;
Matsuba, Chikako (University of Southern California, Los Angeles, USA) ;
Solivellas-Pieras, Maria (Cancer Epigenetics Laboratory. Health Research Institute of the Balearic Islands (IdISBa)) ;
Bedoya-López, Andrés F. (Cancer Epigenetics Laboratory. Health Research Institute of the Balearic Islands (IdISBa)) ;
Sesé, Borja (Cancer Epigenetics Laboratory. Health Research Institute of the Balearic Islands (IdISBa)) ;
Mezger, Anja (Science for Life Laboratory, Solna, Sweden) ;
Ormestad, Mattias (Science for Life Laboratory, Solna, Sweden) ;
Unzueta, Fernando (Universitat de Barcelona) ;
Strand, Siri H. (Stanford University School of Medicine, Stanford, USA) ;
Boiko, Alexander D. (Samuel Oschin Comprehensive Cancer Institute, Los Angeles, USA) ;
Hwang, E.Shelley (Duke University School of Medicine, Durham, USA) ;
Cortés, Javier (Universidad Europea de Madrid) ;
DiNome, Maggie L. (Duke University School of Medicine, Durham, USA) ;
Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lupien, Mathieu (University of Toronto) ;
Marzese, Diego M. (Cancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa))
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which is the first step of the metastatic process. [...]
2023 - 10.1186/s12943-023-01906-8
Molecular cancer, Vol. 22 Núm. 1 (november 2023)
|
|
|
6.
|
|
36 p, 4.7 MB |
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
/
García-Vílchez, Raquel (Instituto de Investigación Biomédica de Salamanca) ;
Añazco-Guenkova, Ana M. (Instituto de Investigación Biomédica de Salamanca) ;
Dietmann, Sabine (Washington University School of Medicine in St. Lou) ;
López, Judith (Instituto de Investigación Biomédica de Salamanca) ;
Morón-Calvente, Virginia (Instituto de Investigación Biomédica de Salamanca) ;
D'Ambrosi, Silvia (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Nombela, Paz (Instituto de Investigación Biomédica de Salamanca) ;
Zamacola, Kepa (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Mendizabal, Isabel (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
García-Longarte, Saioa (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Zabala-Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ;
Astobiza, Ianire (Centro de Investigación Biomédica en Red de Cáncer) ;
Fernández, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ;
Paniagua, Alejandro (Universidad de Salamanca) ;
Miguel-López, Borja (Instituto de Investigación Biomédica de Salamanca) ;
Marchand, Virginie (Université de Lorraine, France) ;
Alonso-López, Diego (Universidad de Salamanca) ;
Merkel, Angelika (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Tuñón, Ignacio (Universidad de Salamanca) ;
Ugalde-Olano, Aitziber (Hospital de Basurto (Bilbao, Biscaia)) ;
Loizaga-Iriarte, Ana (Hospital de Basurto (Bilbao, Biscaia)) ;
Lacasa-Viscasillas, Isabel (Hospital de Basurto (Bilbao, Biscaia)) ;
Unda, Miguel (Hospital de Basurto (Bilbao, Biscaia)) ;
Azkargorta, Mikel (Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Madrid) ;
Elortza, Félix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Bárcena, Laura (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Gonzalez-Lopez, Monika (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Di Domenico, Tomás (Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO)) ;
Sánchez-Martín, Manuel A. (Universidad de Salamanca) ;
De Las Rivas, Javier (Universidad de Salamanca) ;
Guil, S. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Motorin, Yuri (Université de Lorrain) ;
Helm, Mark (Johannes Gutenberg-University Mainz, Germany) ;
Pandolfi, Pier Paolo (University of Turin, Italy) ;
Carracedo, Arkaitz (Centro de Investigación Biomédica en Red de Cáncer) ;
Blanco, Sandra (Universidad de Salamanca)
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. [...]
2023 - 10.1186/s12943-023-01809-8
Molecular cancer, Vol. 22 Núm. 1 (july 2023)
|
|
|
7.
|
|
9 p, 442.2 KB |
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
/
Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ;
Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ;
Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ;
Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ;
Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ;
Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073
|
|
|
8.
|
|
27 p, 8.1 MB |
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
/
Liang, Wen-Wei (Washington University in St. Louis) ;
Lu, Rita Jui-Hsien Lu (Washington University in St. Louis) ;
Jayasinghe, Reyka G. (Washington University in St. Louis) ;
Foltz, Steven M. (Washington University in St. Louis) ;
Porta-Pardo, Eduard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Geffen, Yifat (Massachusetts General Hospital) ;
Wendl, Michael C. (Department of Mathematics. Washington University in St. Louis) ;
Lazcano, Rossana (Departments of Pathology & Genomic Medicine. The University of Texas MD Anderson Cancer Center) ;
Kolodziejczak, Iga (Medical University of Warsaw) ;
Song, Yizhe (Washington University in St. Louis) ;
Govindan, Akshay (Washington University in St. Louis) ;
Demicco, Elisabeth G. (University of Toronto) ;
Li, Xiang (Washington University in St. Louis) ;
Li, Yize (Washington University in St. Louis) ;
Sethuraman, Sunantha (Washington University in St. Louis) ;
Payne, Samuel H. (Department of Biology. Brigham Young University) ;
Fenyö, David (Department of Biochemistry and Molecular Pharmacology. NYU Grossman School of Medicine) ;
Rodriguez, Henry (Office of Cancer Clinical Proteomics Research. National Cancer Institute) ;
Wiznerowicz, Maciej (Poznań University of Medical Sciences) ;
Shen, Hui (Van Andel Research Institute) ;
Mani, D.R. (Broad Institute of Massachusetts Institute of Technology and Harvard) ;
Rodland, Karin D. (Developmental. and Cancer Biology. Oregon Health & Science University) ;
Lazar, Alexander J. (Departments of Pathology & Genomic Medicine. The University of Texas MD Anderson Cancer Center) ;
Robles, Ana I. (Office of Cancer Clinical Proteomics Research) ;
Ding, Li (Washington University in St. Louis) ;
Universitat Autònoma de Barcelona
DNA methylation plays a critical role in establishing and maintaining cellular identity. However, it is frequently dysregulated during tumor development and is closely intertwined with other genetic alterations. [...]
2023 - 10.1016/j.ccell.2023.07.013
Cancer Cell, Vol. 41 Núm. 9 (november 2023) , p. 1567-1585.e7
|
|
|
9.
|
|
5 p, 476.2 KB |
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
/
Castillo, Martín I. (Hospital Clínic Universitari (València)) ;
Ribate, Villamón E. (Hospital Clínic Universitari (València)) ;
Muñoz, Calabuig M. (Hospital Clínic Universitari (València)) ;
Santillana, Sanz G. (Hospital Universitari i Politècnic La Fe (València)) ;
Taboada, Such E. (Hospital Universitari i Politècnic La Fe (València)) ;
Casterá, Mora E. (Hospital Universitari i Politècnic La Fe (València)) ;
Abinzano, Calasanz M.J. (Universidad de Navarra) ;
Barranco, Irigoyen A. (Universidad de Navarra) ;
Nieto, Collado R. (Hospital General Universitario de Valencia) ;
Pampliega, Vara M. (Servicio de Hematología y Hemoterapia del Hospital Universitario de Cruces) ;
Blanco, M. L. (Institut d'Investigació Biomèdica Sant Pau) ;
de Andrés, Álvarez S. (NIMGenetics. Genómica y Medicina) ;
de Oteyza, Pérez J. (Hospital Universitario HM Madrid) ;
del Castillo, Bernal T. (Hospital Universidad de Asturias) ;
Font, Granada I. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cayuela, Jerez A. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Díez-Campelo, M. (Hospital Universitario de Salamanca) ;
Sánchez, Abellán R. (Hospital Clínic Universitari (València)) ;
Vercet, Solano C. (Hospital Clínic Universitari (València)) ;
Díaz, Tormo M. (Hospital Clínico Universitario de Valenciana) ;
Universitat Autònoma de Barcelona
Background: In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown. [...]
2023 - 10.1002/cam4.6300
Cancer Medicine, Vol. 12 Núm. 16 (august 2023) , p. 16788-16792
|
|
|
10.
|
|
8 p, 1.2 MB |
AXL - a new player in resistance to HER2 blockade
/
Adam-Artigues, Anna (INCLIVA Biomedical Research Institute) ;
Arenas, Enrique J (Centro de Investigación Biomédica en Red de Cáncer) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (SOLTI Breast Cancer Research Group) ;
Cejalvo, Juan Miguel (Vall d'Hebron Institut d'Oncologia)
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. [...]
2023 - 10.1016/j.ctrv.2023.102639
Cancer Treatment Reviews, Vol. 121 (december 2023) , p. 102639
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
